A double-blind, randomised, crossover trial of two botulinum toxin type a in patients with spasticity.
Botulinum toxin type A (btxA) is one of the main treatment choices for patients with spasticity. Prosigne® a new released botulinum toxin serotype A may have the same effectiveness as Botox® in focal dystonia. However, there are no randomized clinical trials comparing these formulations in spasticit...
Main Authors: | Fábio Coelho Guarany, Paulo Dornelles Picon, Nicole Ruas Guarany, Antonio Cardoso dos Santos, Bianca Paula Mentz Chiella, Carolina Rocha Barone, Lúcia Costa Cabral Fendt, Pedro Schestatsky |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3585303?pdf=render |
Similar Items
-
The Central Effects of Botulinum Toxin in Dystonia and Spasticity
by: Pavel Hok, et al.
Published: (2021-02-01) -
Botulinum toxin treatment of lower extremity spasticity
by: S. E. Khat’kova, et al.
Published: (2017-11-01) -
Multiple solitary plasmacytoma, spasticity, and botulinum toxin
by: Jamir Pitton Rissardo, et al.
Published: (2021-01-01) -
Guidelines for the use of botulinum toxin in movement disorders and spasticity
by: Jabeen Afshan, et al.
Published: (2011-01-01) -
The Effects of Botulinum Toxin Injections on Spasticity and Motor Performance in Chronic Stroke with Spastic Hemiplegia
by: Yen-Ting Chen, et al.
Published: (2020-07-01)